Phase 2
Completed N=21
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Source: ClinicalTrials.gov NCT04204057 ↗Enrolled (actual)
21
Serious AEs
14.3%
Results posted
Jul 2021
Primary outcomePrimary: Overall Response Rate (ORR) — 33.3 percentage of participants
Summary
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Response Rate (ORR) |
33.3 | — |
| PRIMARY Duration of Response (DoR) |
143 | — |
| SECONDARY Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE Criteria v5.0 |
15 | — |
| SECONDARY Progression Free Survival (PFS) |
205 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with diagnosis of B-cell CLL
- Disease status defined as refractory to or relapsed after at least one prior therapy.
- Presence of measurable lymphadenopathy presence of > 1 nodal lesion
- ECOG performance status ≤ 2.
- Adequate bone marrow, liver, and renal function
Exclusion Criteria
- Richter's (large cell) transformation, or PLL transformation.
- Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5 half-lives (whichever is shorter).
- Prior exposure to drug that inhibits PI3K
- Patient with ASCT/Allo-SCT receiving treatment for active GVHD.
- Ongoing severe systemic bacterial, fungal or viral infection.
- Central nervous system (CNS) involvement of leukemia or lymphoma.
- Ongoing immunosuppressive therapy including systemic corticosteroids.
- Known history of severe liver injury as judge by investigator.
- Any severe and/or uncontrolled medical conditions or other conditions that could affect patient participation
- Women who are pregnant or lactating.
- Known seropositive requiring anti-viral therapy for i. human immunodeficiency virus (HIV) infection. ii. hepatitis B virus (HBV) infection iii. hepatitis c virus (HCV) infection iv. active CMV infection
-
Data sourced from ClinicalTrials.gov (NCT04204057). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.